These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 1417015)

  • 1. [Evaluation of SN-307 (ondansetron), given intravenously in the treatment of nausea and vomiting caused by anticancer drugs including cisplatin--a placebo-controlled, double-blind comparative study].
    Ikeda M; Taguchi T; Ota K; Furue H; Niitani H; Tsukagoshi S; Ariyoshi Y; Akasaka Y; Ohta J; Suminaga M
    Gan To Kagaku Ryoho; 1992 Oct; 19(12):2071-84. PubMed ID: 1417015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Anti-emetic effect and safety of single dose of ondansetron injection in double-blind comparison study with placebo].
    Ohta J; Taguchi T; Furue H; Niitani H; Ota K; Tsukagoshi S; Ariyoshi Y; Ikeda M; Akasaka Y; Suminaga M
    Gan To Kagaku Ryoho; 1992 Oct; 19(12):2041-55. PubMed ID: 1417013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of SN-307 (ondansetron), given intravenously for the treatment of nausea and vomiting caused by anticancer drugs including cisplatin-open study].
    Ikeda M; Taguchi T; Ota K; Furue H; Niitani H; Tsukagoshi S; Ariyoshi Y; Akasaka Y; Ohta J; Suminaga M
    Gan To Kagaku Ryoho; 1992 Sep; 19(11):1905-14. PubMed ID: 1387776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical evaluation of ondansetron (injection of a single intravenous dose) against nausea and emesis associated with anti-cancer drugs--dose-finding study in patients receiving cisplatin].
    Suminaga M; Furue H; Taguchi T; Ota K; Niitani H; Tsukagoshi S; Ariyoshi Y; Ikeda M; Ohta J; Akasaka Y
    Gan To Kagaku Ryoho; 1992 Aug; 19(9):1333-45. PubMed ID: 1386975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anti-emetic effect and safety of ondansetron tablet in double-blind comparison with placebo].
    Ariyoshi Y; Ota K; Taguchi T; Furue H; Niitani H; Tsukagoshi S; Ikeda M; Akasaka Y; Ohta J; Suminaga M
    Gan To Kagaku Ryoho; 1992 Oct; 19(12):2057-70. PubMed ID: 1417014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis].
    Ariyoshi Y; Nukariya N; Akasaka Y; Suminaga M; Ota J; Ikeda M; Taguchi T
    Gan To Kagaku Ryoho; 1997 Jun; 24(8):995-1011. PubMed ID: 9212810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting.
    Cubeddu LX; Hoffmann IS; Fuenmayor NT; Finn AL
    N Engl J Med; 1990 Mar; 322(12):810-6. PubMed ID: 1689807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
    Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-dose ondansetron for the prevention of cisplatin-induced emesis: efficacy results.
    Hainsworth JD; Hesketh PJ
    Semin Oncol; 1992 Dec; 19(6 Suppl 15):14-9. PubMed ID: 1485176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical evaluation of granisetron for nausea and vomiting induced by anticancer drugs--multi-centered placebo-controlled double-blind comparative study].
    Suminaga M; Furue H; Ohta K; Taguchi T; Niitani H; Ogawa N
    Gan To Kagaku Ryoho; 1993 Jul; 20(9):1211-9. PubMed ID: 8392826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: review of clinical trials.
    Beck TM
    Semin Oncol; 1992 Dec; 19(6 Suppl 15):20-5. PubMed ID: 1485178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients.
    Hardy J; Daly S; McQuade B; Albertsson M; Chimontsi-Kypriou V; Stathopoulos P; Curtis P
    Support Care Cancer; 2002 Apr; 10(3):231-6. PubMed ID: 11904788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
    Van Belle S; Lichinitser MR; Navari RM; Garin AM; Decramer ML; Riviere A; Thant M; Brestan E; Bui B; Eldridge K; De Smet M; Michiels N; Reinhardt RR; Carides AD; Evans JK; Gertz BJ
    Cancer; 2002 Jun; 94(11):3032-41. PubMed ID: 12115394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of concurrent use of ondansetron hydrochloride and dexamethasone against nausea and vomiting in lung cancer patients receiving cisplatin].
    Tanimura S; Banba J; Tomoyasu H; Masaki M
    Gan To Kagaku Ryoho; 1998 Dec; 25(14):2275-81. PubMed ID: 9881085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical evaluation of granisetron injection against nausea and vomiting induced by anticancer drugs including cisplatin].
    Yoshiya N; Kodama S; Tanaka K; Hataya I; Tokunaga A; Takeuchi Y; Hanaoka J; Yanase T; Takahashi T; Maruhashi T
    Gan To Kagaku Ryoho; 1994 Aug; 21(10):1641-6. PubMed ID: 8060140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prevention of postoperative nausea and vomiting with single and repeat administration of ondansetron--review of the literature on different administration forms].
    Saur P; Mühr C; Kazmaier S; Neumann P; Buhre W
    Anaesthesiol Reanim; 1996; 21(5):131-5. PubMed ID: 9044556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
    Mantovani G; Macciò A; Bianchi A; Curreli L; Ghiani M; Proto E; Santona MC
    Cancer; 1996 Mar; 77(5):941-8. PubMed ID: 8608488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antiemetic prophylaxis after laparoscopic cholecystectomy: comparative study of dehydrobenzperidol, metoclopramide, ondansetron and placebo].
    Pertusa V; Bellver J; Marqués A; Onrubia X; Viñals MP; Sanmiguel G; Seller JM; Martínez-Carrasco C
    Rev Esp Anestesiol Reanim; 1996; 43(7):239-42. PubMed ID: 8966351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis? The French Navoban Study Group.
    Marty M; Kleisbauer JP; Fournel P; Vergnenegre A; Carles P; Loria-Kanza Y; Simonetta C; de Bruijn KM
    Anticancer Drugs; 1995 Feb; 6 Suppl 1():15-21. PubMed ID: 7749165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.